Filtered By:
Therapy: Neoadjuvant Therapy
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 9957 results found since Jan 2013.
Evidence-Based Strategies to Minimize the Likelihood of Axillary Lymph Node Dissection in Clinically Node-Positive Patients Following Neoadjuvant Chemotherapy
Surg Oncol Clin N Am. 2023 Oct;32(4):693-703. doi: 10.1016/j.soc.2023.05.003. Epub 2023 Jun 9.ABSTRACTDe-escalation of axillary management after neoadjuvant chemotherapy in clinically node-positive patients is feasible. The current literature shows this may be accomplished by sentinel lymph node biopsy (SLNB) with the use of dual tracer and removal of at least 2 sentinel lymph nodes, or by targeted axillary dissection (TAD). The accuracy of TAD has been consistently shown as better than that of SLNB. However, these techniques should only be offered to select patients without extensive axillary disease, understanding that l...
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Ashley A Woodfin Abigail S Caudle Source Type: research
Correlation of an immune-related 8-gene panel with pathologic response to neoadjuvant chemotherapy in patients with primary breast cancers
In conclusion, we have identified eight immune-related genes that are associated with a favorable prognosis and positive responses to drugs. This 8-gene signature could potentially provide prognostic insights for breast cancer patients undergoing NACT.PMID:37713974 | DOI:10.1016/j.tranon.2023.101782
Source: Translational Oncology - September 15, 2023 Category: Cancer & Oncology Authors: Ling-Ming Tseng Chi-Cheng Huang Yi-Fang Tsai Ji-Lin Chen Ta-Chung Chao Jiun-I Lai Pei-Ju Lien Yen-Shu Lin Chin-Jung Feng Yen-Jen Chen Jen-Hwey Chiu Chih-Yi Hsu Chun-Yu Liu Source Type: research
Evidence-Based Strategies to Minimize the Likelihood of Axillary Lymph Node Dissection in Clinically Node-Positive Patients Following Neoadjuvant Chemotherapy
Surg Oncol Clin N Am. 2023 Oct;32(4):693-703. doi: 10.1016/j.soc.2023.05.003. Epub 2023 Jun 9.ABSTRACTDe-escalation of axillary management after neoadjuvant chemotherapy in clinically node-positive patients is feasible. The current literature shows this may be accomplished by sentinel lymph node biopsy (SLNB) with the use of dual tracer and removal of at least 2 sentinel lymph nodes, or by targeted axillary dissection (TAD). The accuracy of TAD has been consistently shown as better than that of SLNB. However, these techniques should only be offered to select patients without extensive axillary disease, understanding that l...
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Ashley A Woodfin Abigail S Caudle Source Type: research
Neoadjuvant triplet chemotherapy with docetaxel, cisplatin plus 5-FU vs docetaxel, cisplatin plus S-1 for advanced esophageal squamous cell carcinoma: Propensity score matched analysis
CONCLUSIONS: Neoadjuvant DCS therapy for resectable advanced ESCC did not result in significantly higher clinical and pathological response than neoadjuvant DCF therapy. However, neoadjuvant DCS therapy for resectable ESCC required comparatively shorter hospital stays and incurred lower costs, making it an attractive therapeutic option.PMID:37708864 | DOI:10.1159/000533790
Source: Oncology - September 14, 2023 Category: Cancer & Oncology Authors: Junya Kitadani Toshiyasu Ojima Keiji Hayata Taro Goda Akihiro Takeuchi Shinta Tominaga Naoki Fukuda Tomoki Nakai Hiroki Yamaue Manabu Kawai Source Type: research
Plasma extracellular vesicle long RNAs predict response to neoadjuvant immunotherapy and survival in patients with non-small cell lung cancer
Pharmacol Res. 2023 Sep 12:106921. doi: 10.1016/j.phrs.2023.106921. Online ahead of print.ABSTRACTNeoadjuvant immunotherapy has brought new hope for patients with non-small cell lung cancer (NSCLC). However, limited by the lack of clinically feasible markers, it is still difficult to select NSCLC patients who respond well and to predict patients' clinical outcomes before the treatment. Before the treatment, we isolated plasma extracellular vesicles (EVs) from three cohorts (discovery, training and validation) of 78 NSCLC patients treated with neoadjuvant immunotherapy. To identify differentially-expressed EV long RNAs (exL...
Source: Cell Research - September 14, 2023 Category: Cytology Authors: Wei Guo Bolun Zhou Liang Zhao Qilin Huai Fengwei Tan Qi Xue Fang Lv Shugeng Gao Jie He Source Type: research
The Effects of High Deductible Health Plans on Breast Cancer Treatment and Reconstruction
CONCLUSION: The cost-sharing burden of HDHPs creates the potential for patients to forego care, and thus, effort should be directed toward increasing patient education concerning health plan benefits. Utilization of postdeductible spending, as well as resources of health savings accounts, may limit the adverse effects of HDHPs. This study also emphasizes the importance for providers to increase cost transparency.PMID:37709587 | DOI:10.1016/j.clbc.2023.08.006
Source: Clinical Genitourinary Cancer - September 14, 2023 Category: Cancer & Oncology Authors: Kaitlin D Jones Alexis C Lakatta Nicholas T Haddock Sumeet S Teotia Source Type: research
Neoadjuvant triplet chemotherapy with docetaxel, cisplatin plus 5-FU vs docetaxel, cisplatin plus S-1 for advanced esophageal squamous cell carcinoma: Propensity score matched analysis
CONCLUSIONS: Neoadjuvant DCS therapy for resectable advanced ESCC did not result in significantly higher clinical and pathological response than neoadjuvant DCF therapy. However, neoadjuvant DCS therapy for resectable ESCC required comparatively shorter hospital stays and incurred lower costs, making it an attractive therapeutic option.PMID:37708864 | DOI:10.1159/000533790
Source: Oncology - September 14, 2023 Category: Cancer & Oncology Authors: Junya Kitadani Toshiyasu Ojima Keiji Hayata Taro Goda Akihiro Takeuchi Shinta Tominaga Naoki Fukuda Tomoki Nakai Hiroki Yamaue Manabu Kawai Source Type: research
Effect of HER2-low expression on neoadjuvant efficacy in operable breast cancer
CONCLUSION: This retrospective study indicates that HER2-low has no significant effect on neoadjuvant efficacy in operable breast cancer. There were no statistical differences in clinical characteristics, pCR rate, and DFS between the HER2-low and the HER2-0 groups. There was no evidence that a HER2-low status constitutes a unique biological subtype, suggesting that more clinical data might be needed to verify these observations.PMID:37702827 | DOI:10.1007/s12094-023-03318-y
Source: Clinical Breast Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Xiaoli Yi Shasha Hu Meili Ma Dongshuai Huang Yan Zhang Source Type: research
Great Debates: Neoadjuvant Therapy Should be Routinely Given for High-Risk Cholangiocarcinoma
Ann Surg Oncol. 2023 Sep 13. doi: 10.1245/s10434-023-14254-0. Online ahead of print.NO ABSTRACTPMID:37702902 | DOI:10.1245/s10434-023-14254-0
Source: Ann Oncol - September 13, 2023 Category: Cancer & Oncology Authors: Hop S Tran Cao Cristina Ferrone Shishir K Maithel Flavio G Rocha Source Type: research
Effect of HER2-low expression on neoadjuvant efficacy in operable breast cancer
CONCLUSION: This retrospective study indicates that HER2-low has no significant effect on neoadjuvant efficacy in operable breast cancer. There were no statistical differences in clinical characteristics, pCR rate, and DFS between the HER2-low and the HER2-0 groups. There was no evidence that a HER2-low status constitutes a unique biological subtype, suggesting that more clinical data might be needed to verify these observations.PMID:37702827 | DOI:10.1007/s12094-023-03318-y
Source: Clinical Genitourinary Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Xiaoli Yi Shasha Hu Meili Ma Dongshuai Huang Yan Zhang Source Type: research
